New Products Page

The GlycoMark test reflects daytime (postprandial) glucose spikes in moderately-controlled patients over a period of 2 days to 2 weeks – making GlycoMark an important clinical tool as an adjunct to A1C testing in maintaining near-normal glycemia. The GlycoMark test measures the serum levels of 1,5-anhydroglucitol (1,5AG), the 1-deoxy form of glucose. When glucose levels are high in diabetic patients, 1,5AG levels decrease within a short period of time as a result of glucose’s competitive inhibition of 1,5AG reabsorption in the kidney.

Andrx Corporation announced that the FDA has given final approval to Fortamet™ (metformin HCl) Extended-Release Tablets, 500 mg and 1000 mg. Once-a-day Fortamet offer improved convenience and a reduction of pill burden for patients.

BMI Calculator for use on Palm OS and PocketPC 2003 Devices

Download your free program for your handheld device. Compliments of the educational mission of the Obesity Education Initiative (OEI) of the NIH National Heart, Lung, and Blood Institute.
Click Here for More

FDA Approves First Insulin Drug Vetsulin ® for Diabetic Dogs
See Item # 5

Children’s Medical Id Bracelet

Many children don't wear medical alert identification because it draws attention to their condition. The Beadin' Beagle now offers a fashionable alternative to the standard medical identification bracelet! For more styles Click Here

LAF237 is the lead DPP-IV inhibitor compound from Novartis.

Preliminary results of 12 week Phase 2 studies show LAF237 was well tolerated and demonstrated surprising glucose-lowering potency both as monotherapy, and in combination with metformin. Novartis is proceeding to Phase 3 Clinical Trials with this compound. See this weeks Item #2. To get slides on how LAF237 works click here.

The Quick-Fix Key Chain

For that emergency hypoglycemic reaction,
you have your glucose tablets with you at all times.
It holds 4 glucose tablets, its refillable and even floats.
Cost is only $4.25 More info:

Flat-D

Last year when I first heard about the Flat-D pad, from Frank Morosky of FLAT-D innovations, I thought it was a joke. But after seeing some of the comments of users and doing some more research into why diabetes patients get gas, I now know why Frank called me. To learn more about the “flatulence pad” and get a free sample click here.

GluCath

A sensor that glows at varying intensities depending on blood sugar concentrations can perform under conditions similar to those in the body GluCath inserted into a blood vessel and gives a continuous blood glucose reading. It uses an optical sensing device.
See Item #6 in this weeks newsletter.

Implantable Continuous Glucose Monitoring System

DexCom, Inc., is focused on developing the first long-term implantable sensor for the continuous monitoring of glucose in people with diabetes. Results from the most recent clinical study with the first generation DexCom provided clinical outcome data suggesting meaningful improvement in the glucose profiles in patients with diabetes using the DexCom continuous glucose monitoring system to help manage their disease.

Liraglutide (NN2211) – Enters Phase 2 Clinical Trials.

Liraglutide is based on a naturally occurring hormone called Glucagon-Like Peptide-1 (GLP-1). Studies to date suggest liraglutide improves control of blood glucose (glycemic control) and may have advantages over current therapies: Learn more here

Warm Feet Kit Warm Feet Therapy
It is a mind-body therapy designed to improve blood flow to the feet (the periphery of the body). It achieves its effect through relaxation training. Multi-site clinical trials have proven significant contribution to pain relief and increased healing of chronic foot ulcers.
See the Results from the Diabetes In Control Warm Feet Study.

Takeda and Andrx are to develop and market a new combination drug for type 2 diabetes. Takeda and Andrx have entered into an agreement to develop and market a combination product for the treatment of type 2 diabetes. The new agent will consist of Takeda's Actos (pioglitazone) and Andrx's Fortamet (metformin extended release), each of which is administered once daily

Exanta (Ximelagatran)by AstraZeneca Pharmaceuticals. A single dose, was found to be as safe and effective as coumadin in preventing clotting. With once aday dosing and short half-life and no monitoring required, it could replace warfarin as the standard in preventing clotting. Read More...

Exanta (Ximelagatran)by AstraZeneca Pharmaceuticals. A single dose, was found to be as safe and effective as coumadin in preventing clotting. With once aday dosing and short half-life and no monitoring required, it could replace warfarin as the standard in preventing clotting.
Regulatory submissions should happen this year for using to prevent strokes. Exanta, is the first oral anticoagulant to reach late stage clinical development in almost 60 years. It's a DIRECT thrombin inhibitor...starts working in HOURS. Warfarin takes several DAYS to deplete clotting factors. Exanta doesn't require dose adjustments...and has a low risk of drug interactions. Routine coagulation monitoring is also not necessary. Expect Exanta to be approved...probably next year

New FDA approved drug for ED Cialis (tadalafil)
See Item #2 Know the differences between Viagra, Cialis and Levitra.

Ezetimibe/Simvastatin ComboTablet
Merck/Schering-Plough Pharmaceuticals Announces Submission of New Drug Application to FDA for Ezetimibe/Simvastatin Tablet, an Investigational Cholesterol-Lowering Medicine
The application was submitted on September 24, 2003 and is the second medicine that Merck/Schering-Plough Pharmaceuticals has submitted to the FDA. If accepted for filing and subsequently approved, ezetimibe/simvastatin would be the first product to reduce cholesterol through dual inhibition by targeting both cholesterol production in the liver and absorption in the intestine.

Oral Solution Metformin
Riomet
(metformin HCl, 500 mg/5 mL) oral solution is approved for use as a monotherapy as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes.
For more information, contact Ranbaxy Pharmaceuticals Inc.

ZYVOX™ 600 mg.
The FDA has approved the antibiotic ZYVOX for the treatment of diabetic foot infections. A completely new class of antibiotic to treat resistant gram positive infections. Pfizer, the manufacturer of the antibiotic, cautions that patients taking ZYVOX should have complete blood counts monitored weekly, noting reports of bone marrow suppression.
For more information
email me.

ShotBlocker

For many of our patients that need to start on insulin, fear of needles is the number one reason why they won’t. I found a product at the recent AAFP conference that helps over come that fear.
It's called ShotBlocker.
More Info

GLUCOBOY MOVES CLOSER TO REALITY

GLUCOBOY® is a glucose meter that can be inserted into a Nintendo GAMEBOY®. GLUCOBOY® carries an essential dual role, providing accurate medical diagnosis for the disease as well as an incentive delivery platform which serves as a key portal for obtaining patient-critical medical data; the foundation for fully automated, individualized, disease management program. Read More..>

Announcement from SimpleChoice

SimpleChoice is pleased to announce the release of the SimpleChoice®Easy brand 30-degree insulin pump infusion set. This infusion set has many unique, innovative features. The larger tape has a water-resistant shield across the entire tape surface. More Info

FLAT-D ™ or the Flatulence (gas) Deodorizer
Flatulence (gas) - we all have it, it is part of life. It is a natural result of good digestion. Passing gas is a more familiar term to many people. Gas pains can be uncomfortable and embarrassing for many people but you can reduce the symptoms and find relief……. More...>